NeoGenomics Inc. (NASDAQ: NEO) shares traded higher in the last trading session, rising 7.87% on 3/31/21. The stock fell to a low of $ 44.79 before closing at $ 48.23. The intraday stocks traded were 2.36 million, -124.43% below the average 30-day trading volume of 1.05 million. NEO’s previous closing price was $ 44.71 while its shares outstanding totaled $ 111.50 million. The company has a beta of 0.70, a trailing 12 month P / E of 1507.19, and a growth ratio of 75.36. The stock’s Relative Strength Index (RSI) is 48.48 with a weekly volatility of 5.89% and an ATR of 2.93. The 52-week price range of NEO stock has hit a low of $ 24.05 and a high of $ 61.57.
Investors have identified Diagnostics & Research firm NeoGenomics Inc. as an interesting stock, but an in-depth review of its trading activities must be conducted before investing there. The stock is traded at a market value of approximately $ 5.60 billion. The company now has both obstacles and catalysts that affect them, and they stem from its operations. With events hit the company right now, it’s a perfect time to analyze the numbers behind the company for a fairly realistic picture of what this stock is.
NeoGenomics Inc. (NEO) fundamentals to consider.
When analyzing a stock, the first thing to consider is the balance sheet. How healthy a company’s balance sheet is depends on the company’s ability to meet all financial and non-financial obligations and maintain the confidence of its investors. In terms of their assets, the company currently has a total of $ 448.73 million, with $ 73.18 million in total liabilities.
Looking at the company’s valuation, the company is expected to achieve total earnings per share of 0.33 for the next fiscal year. However, it is very important to remember that the importance of the trend far outweighs that of the outlook. That analysis was great and it sounds very interesting to receive more updates on NEO.
Is NEO stock attractive?
In related news, Chief Medical Officer Weiss Lawrence Martin sold 20,200 shares in the company in a transaction that was recorded on Dec. 14. The sale was conducted at an average price of 51.06 for a total value of 1,031,412. At the end of the sale, Director JONES STEVEN C has now sold 25,000 shares in the company for a total of 1,291,750. In addition, BALLIET JENNIFER, VP and Chief Culture Officer, sold 15,000 shares in the company in a deal recorded December 11th. The shares were valued at an average price of 49.99 per share with a total market value of 749,850 shares. Upon completion of the acquisition, Director, JONES STEVEN C, now holds 25,000 shares in the company valued at 1,263,000. In the past 6 months, Insiders have changed their stake in the company’s stock by 2.90%.
11 out of 12 analysts covering the stock have given it a “buy” rating, while 1 has maintained a hold rating for NeoGenomics Inc. 0 analysts have assigned a sell rating to the NEO share. The average consensus price target for the company’s stock for 12 months has been set at $ 63.20.